SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Deel strikes multi-year deal with Arsenal as tech firm enters global sport

Jensen Huang’s quiet role emerges as Argamani describes Nvidia’s two-year vigil for Avinatan Or

Freed Nvidia engineer Avinatan Or meets Jensen Huang at U.S. headquarters

Palo Alto Networks: Hamas-linked hackers launch stealth espionage push across Arab governments

Buzz

Most popular

Daily

Weekly

1

Oracle’s stock has fallen 40% since Safra Catz announced her exit. Its latest earnings didn’t calm investors.

2

Freed Nvidia engineer Avinatan Or meets Jensen Huang at U.S. headquarters

3

After over $390 million in funding, Believer Meats abruptly shuts down

4

Israel’s quantum boom: Startups hit $500 million in funding in 2025

5

BlackRock in talks for major investment in creative-tech firm Artlist

Pharmaceuticals

7 stories about Pharmaceuticals

Pharma Companies Arcturus Therapeutics and Alcobra to Merge

28.09.17|Lilach Baumer

The merged entity will develop treatments for infectious diseases, cystic fibrosis, and rare liver diseases

MeMed מכשיר לזיהוי זיהום ב דם

Automated Medical Diagnosis Startup Raises $30 Million

19.09.17|Omer Kabir

Israel-based MeMed develops an automated blood testing device that can distinguish between bacterial and viral infections. The company previously raised funds from the U.S. Department of Defense

חברת ה תרופות טבע Teva

Teva Sells Remaining Women's Health Assets

18.09.17|Lilach Baumer

After selling its Paragard business for $1.1 billion last week, Teva's remaining Women's Health business will be split between CVC Capital Partners and Foundation Consumer Healthcare in a $1.38 billion cash deal

מפעל חברת טבע הר חוצבים ירושלים

Teva Negotiating Sale of Remaining Women's Health Assets, Report Says

14.09.17|Lilach Baumer

CVC Capital Partners is nearing a $800 million deal for Teva's remaining Women's Health business, Bloomberg reported Thursday

IPO Hopeful Entera Bio Moves to Better Position

13.09.17|Dror Reich

Clinical-stage company Entera Bio develops pioneering technology for orphan disease hypoparathyroidism

מנכ"ל טבע החדש קור שולץ

The Ten Challenges Facing Teva's New CEO

12.09.17|Sophie Shulman

Kåre Schultz is the right man for the job, but he's facing multiple problems, from a changing market to a problematic board

קור שולץ מנכ"ל טבע החדש

Teva Appoints Lundbeck's Schultz as CEO

11.09.17|Dror Reich and Micky Grunfeld

The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated

Previous Articles